41 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
Research and development
Clinical development
Selling, general and administrative
Depreciation and amortization
Total operating expenses
Loss from operations … segments, Diagnostic Research and Development (R&D) and Laboratory Services, whereby its chief operating decision maker (“CODM”) assesses the performance
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
Statements of Operations
Three Months Ended
March 31,
(unaudited)
Net Revenue
Operating expenses:
Direct costs and expenses
Research and development … Research and Development (R&D) and Laboratory Services, whereby its chief operating decision maker (“CODM”) assesses the performance of and allocates
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
Lung tests, with additional revenues generated from histology service fees and medical director fees.
Research and development expenses were $394,000 … Consolidated Statements of Operations
Three Months Ended
March 31,
(unaudited)
Net Revenue
Operating expenses:
Direct costs and expenses
Research
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
Populations in Lung Cancer Screening Patients Using the CyPath® Lung Assay,” and for research and development on using bronchoalveolar lavage fluid … was opened by Brooke Army Medical Center in March 2023 to collect bronchoalveolar lavage samples to advance the research and development of a lung
POS AM
pw7xp4zr8r6 2b7p
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-99.1
wakzx4c o3
1 Apr 24
Results of Operations and Financial Condition
4:00pm
424B5
qnik3job82hcb2 oh
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
r4tbs4
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-10.1
q7y5f7
31 Jan 24
Departure of Directors or Certain Officers
4:05pm
424B5
54urvnkwjboo1eaz
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
yo2atjp
16 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
85az7g8ia
15 Nov 23
Results of Operations and Financial Condition
5:07pm
8-K
EX-99.3
qr6h uxx2tsk
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm